Scientists have claimed that they have found the first complete cure for cancer – and it will be offered to us within the year.
The small team of Israeli scientists are confident that their cure will be ‘effective from day one’ and will be made available within the next 12 months.
The treatment, called MuTaTo, will reportedly use a combination of cancer-targeting peptides and a toxin that will specifically kill cancer cells.
As reported by The Jerusalem Post, the company behind the treatment is Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded nearly 20 years ago in 2000.
Dan Aridor, chairman of the company’s board, told The Jerusalem Post:
We believe we will offer in a year’s time a complete cure for cancer.
Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market. Our solution will be both generic and personal.
MuTaTo – multi-target toxin – will essentially be a cancer ‘antibiotic’, Aridor and CEO Dr Ilan Morad claim.
The company initially tried to do what everyone else was doing, but quickly realised that this would not work, the CEO claims.
Instead, they set out trying to identify why other cancer-killing drugs and treatments either don’t work at all or eventually fail. Once they figured that out, the company say they then had to find a way to counter that effect.
First off, they found that most anti-cancer drugs attack a specific target on or in cancer cells, Morad explained. This treatment allegedly fails because the target then mutates – dividing and spreading to avoid attack. Because of this, the drug attacking the specific target is rendered useless and therefore fails to work.
Dr Morad insists that MuTaTo will not fail in this way; instead, it will use a combination of several cancer-targeting peptides for each cancer cell at the same time, and a strong peptide toxin that will kill cancer cells specifically.
This will ensure that the treatment is not affected by mutations, because the treatment attacks three targets at a time.
We made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer.
The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used. Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.
The scientist also claims that the drug could reduce the side-effects of most cancer treatments, and the drug will eventually be personalised to each patient.
However, Morad admits that the company has so far only conducted its experiments on mice, meaning clinical human trials are needed.
And while he says the company is on the cusp of conducting these trials, it may take ‘a few years’ to complete them.
If you have a story you want to tell, send it to [email protected]